Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04075370 · ClinicalTrials.gov registry record
Exploring Compensation to Maintain Cognitive Function in Adults Newly Diagnosed With Brain Cancer
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 33
- Enrollment target
NCT04075370: Completed study, sponsored by Duke University.
NCT04075370 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04075370 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
Recent research indicates that variability in cognitive function for brain tumor survivors may be explained by differences in cognitive reserve (CR) and use of compensatory strategies.However, it is unknown when cognitive function declines or survivors tap into compensation. This longitudinal mixed methods study proposes to explore differences in cognitive function and change over time in newly diagnosed adults with brain cancer prior to, immediately after (within 2 weeks), and 2-3 months after radiation therapy treatment has been completed. Specific aims are to: Aim1: Examine the relationship between objective and subjective cognitive function in subjects newly diagnosed with brain cancer prior to and after XRT. Aim 2: Explore the interrelationship between cognitive function and compensation (neural and behavioral) by high/low CR prior to and after XRT. Aim 3: Describe the trajectory of objective and subjective cognitive function over time by CR, cancer type, and associated treatment-related factors.
Primary Outcome
Serial neurocognitive testing using composite scores from the Trail Making A and B test
Interventions
- OTHER Neuropsychological Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-07-22 |
| Est. Completion | 2022-12-31 |
What the finished NCT04075370 record still lists
NCT04075370 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Neuropsychological Testing is the first listed.
NCT04075370 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04075370 about?
NCT04075370 is a clinical study titled "Exploring Compensation to Maintain Cognitive Function in Adults Newly Diagnosed With Brain Cancer". Recent research indicates that variability in cognitive function for brain tumor survivors may be explained by differences in cognitive reserve (CR) and use of compensatory strategies.However, it is unknown when cognitive function declines or survivors tap into compensation. This longitudinal mixed ...
What is the current status of trial NCT04075370?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2021-07-22. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT04075370?
The interventions under investigation include: Neuropsychological Testing (OTHER).
Who is sponsoring clinical trial NCT04075370?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI